JP6441906B2 - ヒト凝固因子軽鎖タンパク質及びその使用 - Google Patents

ヒト凝固因子軽鎖タンパク質及びその使用 Download PDF

Info

Publication number
JP6441906B2
JP6441906B2 JP2016515629A JP2016515629A JP6441906B2 JP 6441906 B2 JP6441906 B2 JP 6441906B2 JP 2016515629 A JP2016515629 A JP 2016515629A JP 2016515629 A JP2016515629 A JP 2016515629A JP 6441906 B2 JP6441906 B2 JP 6441906B2
Authority
JP
Japan
Prior art keywords
lhf
protein
vii
recombinant
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016515629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521685A (ja
JP2016521685A5 (enExample
Inventor
シュー ソン
シュー ソン
リン リー
リン リー
ジンウー チェン
ジンウー チェン
ドンシェン リアオ
ドンシェン リアオ
デンジャオ マー
デンジャオ マー
Original Assignee
チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー
チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー, チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー filed Critical チョントゥー ソースバイオ リミテッド ライアビリティ カンパニー
Publication of JP2016521685A publication Critical patent/JP2016521685A/ja
Publication of JP2016521685A5 publication Critical patent/JP2016521685A5/ja
Application granted granted Critical
Publication of JP6441906B2 publication Critical patent/JP6441906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016515629A 2013-05-29 2014-05-22 ヒト凝固因子軽鎖タンパク質及びその使用 Active JP6441906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310206823.5 2013-05-29
CN201310206823.5A CN104211802B (zh) 2013-05-29 2013-05-29 人凝血因子轻链蛋白及其应用
PCT/CN2014/078108 WO2014190871A1 (zh) 2013-05-29 2014-05-22 人凝血因子轻链蛋白及其应用

Publications (3)

Publication Number Publication Date
JP2016521685A JP2016521685A (ja) 2016-07-25
JP2016521685A5 JP2016521685A5 (enExample) 2017-07-06
JP6441906B2 true JP6441906B2 (ja) 2018-12-19

Family

ID=51987992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515629A Active JP6441906B2 (ja) 2013-05-29 2014-05-22 ヒト凝固因子軽鎖タンパク質及びその使用

Country Status (5)

Country Link
US (1) US9782461B2 (enExample)
EP (1) EP3006461A4 (enExample)
JP (1) JP6441906B2 (enExample)
CN (2) CN104211802B (enExample)
WO (1) WO2014190871A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111272889B (zh) * 2020-02-10 2022-02-25 济宁学院 基于蛋白质组学定量技术分析嗜水气单胞菌感染日本沼虾血细胞差异表达蛋白质的方法
CN116539893B (zh) * 2023-04-23 2026-02-13 天津医科大学总医院 一种细胞内凝血因子ⅹ的质谱检测方法、应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5940799A (en) * 1994-10-24 2000-02-17 Novo Nordisk A/S Modified factor VII
WO2002102319A2 (en) * 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
WO2004108763A2 (en) * 2003-06-05 2004-12-16 Canadian Blood Services Mutants of the factor vii epidermal growth factor domain
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
CN101384613A (zh) * 2006-02-10 2009-03-11 德玛根股份公司 新型抗微生物肽及其应用
US7968683B1 (en) * 2008-05-07 2011-06-28 Schering Corporation Factor IXa crystals, related complexes and methods
CA2806111A1 (en) * 2010-07-22 2012-01-26 Hansa Medical Ab An ancestral serine protease coagulation cascade exerts a novel function in early immune defense
FR2972114B1 (fr) * 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
CN102875685B (zh) * 2012-09-29 2013-12-25 郑骏年 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途

Also Published As

Publication number Publication date
CN105473611A (zh) 2016-04-06
CN104211802A (zh) 2014-12-17
US9782461B2 (en) 2017-10-10
JP2016521685A (ja) 2016-07-25
EP3006461A1 (en) 2016-04-13
WO2014190871A1 (zh) 2014-12-04
CN105473611B (zh) 2020-03-20
EP3006461A4 (en) 2017-01-25
US20160106818A1 (en) 2016-04-21
CN104211802B (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
JP6585085B2 (ja) Ｕｓｐａ２タンパク質構築物およびそれらの使用
Seo et al. Purification and characterization of YFGAP, a GAPDH-related novel antimicrobial peptide, from the skin of yellowfin tuna, Thunnus albacares
EP3010932B1 (en) Bacterial hyaluronidase and process for its production
KR20220044811A (ko) Crispr/cas13을 사용하는 표적화된 트랜스-이어맞추기
JP6503342B2 (ja) ヒト起源ｅｇｆドメインタンパク質及びその使用
TW202222821A (zh) 用於預防及/或治療covid-19之組合物及方法
US20200024365A1 (en) mRNA-ENCODED NANOBODY AND APPLICATION THEREOF
Wang et al. FADD cooperates with Caspase-8 to positively regulate the innate immune response and promote apoptosis following bacterial infection in Japanese eel
CN103088050B (zh) 一种成熟人β防御素-2及其制备方法
JP2016521685A (ja) ヒト凝固因子軽鎖タンパク質及びその使用
WO2013079207A1 (en) Novel targets of acinetobacter baumannii
JP6034385B2 (ja) 病原体を防除するためのアミノ酸配列
CN106432459A (zh) 花姬蛙抗菌肽及其基因和在制药中的应用
CN117551204A (zh) 一种靶向pcsk9和angptl3的双特异性抗体及其制备方法与应用
CN114989266A (zh) 一种非洲猪瘟病毒pA104R蛋白免疫抑制相关氨基酸位点及其应用
Li et al. On-resin cleavage of bacterially expressed fusion proteins for purification of active recombinant peptides SK-29, KR-20, LL-29, and LL-23 from human sweat or skin
CN100529065C (zh) 一种包含bpi基因的重组病毒及含有其的药物组合物及其用途
WO2023020615A1 (en) Efficient expression system of sars-cov-2 receptor binding domain (rbd), methods for purification and use thereof
KR20260028774A (ko) 양이온성 지질을 함유하는 약학적 조성물 및 이의 용도
HK40111214A (en) Fusion protein containing truncated iga protease and use thereof
HK40111214B (en) Fusion protein containing truncated iga protease and use thereof
CN121064280A (zh) 一种抗肝癌hla-a*02型疫苗及其制备方法和应用
WO2021206183A1 (ja) 機能性ポリぺプチド及びその使用
CN117122673A (zh) 人凝血因子ⅻ重链蛋白的应用
CN1475506A (zh) 具有抑制血管生成及抗肿瘤作用的强化融合蛋白Fv-LDP-AE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181122

R150 Certificate of patent or registration of utility model

Ref document number: 6441906

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250